Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria

Nature Microbiology

Volumn 2, Issue 3, 2017, Pages

  Masi, Muriel ^a   Réfregiers, Matthieu ^b   Pos, Klaas M ^c   Pagès, Jean Marie ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b SYNCHROTRON SOLEIL   (France)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DOXORUBICIN; ERYTHROMYCIN; IMIPENEM; MEROPENEM; MINOCYCLINE; OUTER MEMBRANE PROTEIN F; RESAZURIN; RIFAMPICIN; ANTIINFECTIVE AGENT; CARRIER PROTEIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIAL VIABILITY; CHEMICAL STRUCTURE; CRYSTALLIZATION; DRUG ACCUMULATION; DRUG CONCENTRATION; DRUG DIFFUSION; DRUG MECHANISM; DRUG PENETRATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; EFFUSION; ELECTROPHYSIOLOGY; ENTEROBACTER; ESCHERICHIA COLI; FLUOROMETRY; GRAM NEGATIVE BACTERIUM; INNER MEMBRANE; KLEBSIELLA PNEUMONIAE; MASS SPECTROMETRY; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; NEISSERIA GONORRHOEAE; NEW SPECIES; NONHUMAN; OUTER MEMBRANE; POPULATION DYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ULTRAVIOLET SPECTROPHOTOMETRY; ACTIVE TRANSPORT; CELL MEMBRANE; CELL WALL; DIFFUSION; DRUG EFFECT; METABOLISM; PERMEABILITY;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL MEMBRANE; CELL WALL; DIFFUSION; GRAM-NEGATIVE BACTERIA; MEMBRANE TRANSPORT PROTEINS; PERMEABILITY;

EID: 85018183518     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/nmicrobiol.2017.1     Document Type: Article

References (86)

1. Fraimow, H. S. & Tsigrelis, C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit. Care Clin. 27, 163-205 (2011).
2. Antibiotic Resistance Threats in the United States (Centers for Disease Control and Prevention, 2013).
3. Pierluigi, V., Maddalena, G., Sara, T. & Russell, L. Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Curr. Opin. Pharmacol. 24, 30-37 (2015).
4. Page, M. G. & Bush, K. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr. Opin. Pharmacol. 18, 91-97 (2014).
5. Boucher, H. W. et al. 10 x '20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56, 1685-1694 (2013).
6. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67, 593-656 (2003).
7. Zgurskaya, H. I., López, C. A. & Gnanakaran, S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect. Dis. 1, 512-522 (2015).
8. Pagès, J.-M., James, C. E. & Winterhalter, M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 6, 893-903 (2008).
9. Delcour, A. H. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta 1794, 808-816 (2009).
10. Ruiz, N., Kahne, D. & Silhavy, T. J. Advances in understanding bacterial outer-membrane biogenesis. Nat. Rev. Micro. 4, 57-66 (2006).
11. Li, Z. H., Plesiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Micro. Rev. 28, 337-418 (2015).
12. Bergen, P. J. et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 35, 34-42 (2015).
13. Vaara, M. Polymyxins and novel derivatives. Curr. Opin. Microbiol. 13, 574-581 (2010).
14. Urfer, M. et al. A peptidomimetic antibiotic targets outer membrane proteins and disrupts selectively the outer membrane in Escherichia coli. J. Biol. Chem. 291, 1921-1932 (2016).
15. Silver, L. L. Challenges of antibacterial discovery. Clin. Micro. Rev. 24, 71-109 (2011).
16. Nikaido, H. & Pagès, J.-M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36, 340-363 (2012).
17. Cowan, S. W. et al. Crystal structures explain functional properties of two E. coli porins. Nature 358, 727-733 (1992).
18. Baslé, A., Rummel, G., Storici, P., Rosenbusch, J. P. & Schirmer, T. Crystal structure of osmoporin OmpC from E. coli at 2.0 A. J. Mol. Biol. 362, 933-942 (2006).
19. Yoshimura, F. & Nikaido, H. Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob. Agents Chemother. 27, 84-92 (1985).
20. Nikaido, H. & Rosenberg, E. Y. Porin channels in Escherichia coli: studies with liposomes reconstituted from purified proteins. J. Bacteriol. 153, 241-252 (1983).
21. Zimmermann, W. & Rosselet, A. Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics. Antimicrob. Agents Chemother. 12, 368-372 (1977).
22. Nikaido, H., Rosenberg, E. Y. & Foulds, J. Porin channels in Escherichia coli: studies with beta-lactams in intact cells. J. Bacteriol. 153, 232-240 (1983).
23. Nikaido, H. & Normark, S. Sensitivity of Escherichia coli to various beta-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic beta-lactamases: a quantitative predictive treatment. Mol. Microbiol. 1, 29-36 (1987).
24. Kojima, S. & Nikaido, H. Permeation rates of penicillins indicate that Escherichia coli porins function principally as nonspecific channels. Proc. Natl Acad. Sci. USA 110, 2629-2634 (2013).
25. Kojima, S. & Nikaido, H. High salt concentrations increase permeability through OmpC channels of Escherichia coli. J. Biol. Chem. 289, 26464-26473 (2014).
26. Benz, R., Schmid, A. & Hancock, R. E. Ion selectivity of Gram-negative bacterial porins. J. Bacteriol. 162, 722-727 (1985).
27. Winterhalter, M. & Ceccarelli, M. Physical methods to quantify small antibiotic molecules uptake into Gram-negative bacteria. Eur. J. Pharm. Biopharm. 95, 63-67 (2015).
28. Nestorovich, E. M., Danelon, C., Winterhalter, M. & Bezrukov, S. M. Designed to penetrate: time-resolved interaction of single antibiotic molecules with bacterial pores. Proc. Natl Acad. Sci. USA 99, 9789-9794 (2002).
29. Danelon, C., Nestorovich, E. M., Winterhalter, M., Ceccarelli, M. & Bezrukov, S. M. Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophys. J. 90, 1617-1627 (2006).
30. Simonet, V., Malléa, M. & Pagès, J.-M. Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel. Antimicrob. Agents Chemother. 44, 311-315 (2000).
31. Charrel, R. N., Pagès, J.-M., De Micco, P. & Mallea, M. Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob. Agents Chemother. 40, 2854-2858 (1996).
32. Hernández-Allés, S. et al. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 145, 673-679 (1999).
33. Lavigne, J. P. et al. An adaptive response of Enterobacter aerogenes to imipenem: regulation of porin balance in clinical isolates. Int. J. Antimicrob. Agents 41, 130-136 (2013).
34. Philippe, N. et al. In vivo evolution of bacterial resistance in two cases of Enterobacter aerogenes infections during treatment with imipenem. PLoS ONE 10, e0138828 (2015).
35. Low, A. S., MacKenzie, F. M., Gould, I. M. & Booth, I. R. Protected environments allow parallel evolution of a bacterial pathogen in a patient subjected to long-term antibiotic therapy. Mol. Microbiol. 42, 619-630 (2001).
36. Dé, E. et al. A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol. Microbiol. 41, 189-198 (2001).
37. Thiolas, A., Bornet, C., Davin-Régli, A., Pagès, J.-M. & Bollet, C. Resistance to imipenem, cefepime, and cefpirome associated with mutation in Omp36 osmoporin of Enterobacter aerogenes. Biochem. Biophys. Res. Commun. 317, 851-856 (2004).
38. Giraud, A. et al. Dissecting the genetic components of adaptation of Escherichia coli to the mouse gut. PLoS Genet. 4, e2 (2008).
39. Lou, H. et al. Altered antibiotic transport in OmpC mutants isolated from a series of clinical strains of multi-drug resistant E. coli. PLoS ONE 6, e25825 (2011).
40. Bajaj, H. et al. Molecular basis of filtering carbapenems by porins from β-lactam-resistant clinical strains of Escherichia coli. J. Biol. Chem. 291, 2837-2847 (2016).
41. James, C. E. et al. How beta-lactam antibiotics enter bacteria: a dialogue with the porins. PLoS ONE 4, e5453 (2009).
42. Ziervogel, B. K. & Roux, B. The binding of antibiotics in OmpF porin. Structure 21, 76-87 (2013).
43. Pag?s, J.-M., Peslier, S., Keating, T. A., Lavigne, J. P. & Nichols, W. W. The role of the outer membrane and porins in the susceptibility of β-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob. Agents Chemother. 60, 1349-1359 (2015).
44. Du, D., van Veen, H. W., Murakami, S., Pos, K. M. & Luisi, B. F. Structure, mechanism and cooperation of bacterial multidrug transporters. Curr. Opin. Struct. Biol. 33, 76-91 (2015).
45. Shuster, Y., Steiner-Mordoch, S., Alon-Cudkowicz, N. & Schuldiner, S. A. Transporter interactome is essential for the acquisition of antimicrobial resistance to antibiotics. PLoS ONE 11, e0152917 (2016).
46. Yamaguchi, A., Nakashima, R. & Sakurai, K. Structural basis of RND-type multidrug exporters. Front. Microbiol. 6, 327 (2015).
47. Pos, K. M. Drug transport mechanism of the AcrB efflux pump. Biochim. Biophys. Acta 1794, 782-793 (2009).
48. Nikaido, H. & Takatsuka, Y. Mechanisms of RND multidrug efflux pumps. Biochim. Biophys. Acta 1794, 769-781 (2009).
49. Murakami, S., Nakashima, R., Yamashita, E. & Yamaguchi, A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419, 587-593 (2002).
50. Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T. & Yamaguchi, A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443, 173-179 (2006).
51. Seeger, M. A. et al. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 313, 1295-1298 (2006).
52. Sennhauser, G. et al. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 5, e7 (2007).
53. Sennhauser, G., Bukowska, M. A., Briand, C. & Grütter, M. G. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J. Mol. Biol. 389, 134-145 (2009).
54. Bolla, J. R. et al. Crystal structure of the Neisseria gonorrhoeae MtrD inner membrane multidrug efflux pump. PLoS ONE 9, e97903 (2014).
55. Eicher, T. et al. Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc. Natl Acad. Sci. USA 109, 5687-5692 (2012).
56. Eicher, T. et al. Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB. eLife 3, e03145 (2014).
57. Nakashima, R., Sakurai, K., Yamasaki, S., Nishino, K. & Yamaguchi, A. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 480, 565-569 (2011).
58. Nakashima, R. et al. Structural basis for the inhibition of bacterial multidrug exporters. Nature 500, 102-106 (2013).
59. Sjuts, H. et al. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives. Proc. Natl Acad. Sci. USA 113, 3509-3514 (2016).
60. Du, D. et al. Structure of the AcrAB-TolC multidrug efflux pump. Nature 509, 512-515 (2014).
61. Kim, J. S. et al. Structure of the tripartite multidrug efflux pump AcrAB-TolC suggests an alternative assembly mode. Mol. Cells 38, 180-186 (2015).
62. Daury, L. et al. Tripartite assembly of RND multidrug efflux pumps. Nat. Commun. 7, 10731 (2016).
63. Kühlbrandt, W. Cryo-EM enters a new era. eLife 3, e03678 (2014).
64. Verchère, A., Dezi, M., Adrien, V., Broutin, I. & Picard, M. In vitro transport activity of the fully assembled MexAB-OprM efflux pump from Pseudomonas aeruginosa. Nat. Commun. 6, 6890 (2015).
65. Chapman, J. S. & Georgopapadakou, N. H. Fluorometric assay for fleroxacin uptake by bacterial cells. Antimicrob. Agents Chemother. 33, 27-29 (1989).
66. June, C. M. et al. A fluorescent carbapenem for structure function studies of penicillin-binding proteins, β-lactamases, and β-lactam sensors. Anal. Biochem. 463, 70-74 (2014).
67. Zhou, Y. et al. Thinking outside the "bug": a unique assay to measure intracellular drug penetration in Gram-negative bacteria. Anal. Chem. 87, 3579-3584 (2015).
68. Kinana, A. D., Vargiu, A. V., May, T. & Nikaido, H. Aminoacyl β-naphthylamides as substrates and modulators of AcrB multidrug efflux pump. Proc. Natl Acad. Sci. USA 113, 1405-1410 (2016).
69. Davis, T. D., Gerry, C. J. & Tan, D. S. General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem. Biol. 9, 2535-2544 (2014).
70. Kaščáková, S., Maigre, L., Chevalier, J., Réfrégiers, M. & Pagès, J.-M. Antibiotic transport in resistant bacteria: synchrotron UV fluorescence microscopy to determine antibiotic accumulation with single cell resolution. PLoS ONE 7, e38624 (2012).
71. Cinquin, B. et al. Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level. Sci. Rep. 5, 17968 (2015).
72. Pu, Y. et al. Enhanced efflux activity facilitates drug tolerance in dormant bacterial cells. Mol. Cells 62, 284-294 (2016).
73. Burns, A. R. et al. A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans. Nat. Chem. Biol. 6, 549-557 (2010).
74. Brown, A. R. et al. A mass spectrometry-based assay for improved quantitative measurements of efflux pump inhibition. PLoS ONE 10, e0124814 (2015).
75. Bolla, J. M. et al. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. FEBS Lett. 585, 1682-1690 (2011).
76. Bergen, P. J. et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 35, 34-42 (2015).
77. de Carvalho, C. C. C. R. & Fernandes, P. Siderophores as "Trojan Horses": tackling multidrug resistance? Front. Microbiol. 5, 290 (2014).
78. Mislin, G. L. & Schalk, I. J. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6, 408-420 (2014).
79. Dreier, J. & Ruggerone, P. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front. Microbiol. 6, 660 (2015).
80. Lomovskaya, O. & Bostian, K. A. Practical applications and feasibility of efflux pump inhibitors in the clinic -a vision for applied use. Biochem. Pharmacol. 71, 910-918 (2006).
81. Pagès, J.-M., Amaral L. & Fanning, S. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat Gram-negative resistant bacteria. Curr. Med. Chem. 18, 2969-2980 (2011).
82. Sánchez-Romero, M. A. & Casadesús, J. Contribution of phenotypic heterogeneity to adaptive antibiotic resistance. Proc. Natl Acad. Sci. USA 111, 355-360 (2014).
83. Opperman, T. J. & Nguyen S. T. Recent advances toward a molecular mechanism of efflux pump inhibition. Front. Microbiol. 6, 421 (2015).
84. Dörr, T., Vuli, C., M. & Lewis, K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8, e1000317 (2010).
85. Maisonneuve, E. & Gerdes, K. Molecular mechanisms underlying bacterial persisters. Cell 157, 539-548 (2014).
86. Nagano, K. & Nikaido, H. Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli. Proc. Natl Acad. Sci. USA 106, 5854-5858 (2009).